Using machine learning to identify diabetes patients with canagliflozin prescriptions at high‐risk of lower extremity amputation using real‐world data

Abstract

Our machine learning model efficiently predicted the risk of LEA among diabetes patients undergoing canagliflozin treatment. The risk score may support optimized treatment decisions and thus improve health outcomes of diabetes patients.